|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC7A14 |
Gene summary for SLC7A14 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC7A14 | Gene ID | 57709 |
| Gene name | solute carrier family 7 member 14 | |
| Gene Alias | PPP1R142 | |
| Cytomap | 3q26.2 | |
| Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | Q8TBB6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57709 | SLC7A14 | HCC1 | Human | Liver | HCC | 1.38e-10 | 1.55e+00 | 0.5336 |
| 57709 | SLC7A14 | HCC2 | Human | Liver | HCC | 1.62e-21 | 1.09e+00 | 0.5341 |
| 57709 | SLC7A14 | HCC5 | Human | Liver | HCC | 2.95e-14 | 1.11e+00 | 0.4932 |
| 57709 | SLC7A14 | S014 | Human | Liver | HCC | 7.96e-04 | 2.73e-01 | 0.2254 |
| 57709 | SLC7A14 | S016 | Human | Liver | HCC | 3.81e-08 | 3.58e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC7A14 | SNV | Missense_Mutation | rs371104588 | c.1067C>T | p.Pro356Leu | p.P356L | Q8TBB6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A3KD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| SLC7A14 | SNV | Missense_Mutation | rs146144886 | c.691N>A | p.Ala231Thr | p.A231T | Q8TBB6 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A2-A3XY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | PD |
| SLC7A14 | SNV | Missense_Mutation | novel | c.2216N>A | p.Ala739Glu | p.A739E | Q8TBB6 | protein_coding | tolerated(1) | benign(0) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| SLC7A14 | SNV | Missense_Mutation | c.32N>A | p.Arg11Gln | p.R11Q | Q8TBB6 | protein_coding | tolerated_low_confidence(0.11) | possibly_damaging(0.625) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC7A14 | SNV | Missense_Mutation | c.1312G>A | p.Asp438Asn | p.D438N | Q8TBB6 | protein_coding | tolerated(0.2) | benign(0.196) | TCGA-B6-A0I6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| SLC7A14 | SNV | Missense_Mutation | c.82C>T | p.Arg28Cys | p.R28C | Q8TBB6 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-D8-A1XS-01 | Breast | breast invasive carcinoma | Male | <65 | III/IV | Chemotherapy | adriamycin+cyclophosphamide | SD | |
| SLC7A14 | SNV | Missense_Mutation | rs745969616 | c.2244N>C | p.Lys748Asn | p.K748N | Q8TBB6 | protein_coding | tolerated(0.1) | benign(0.001) | TCGA-E9-A22A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| SLC7A14 | insertion | Frame_Shift_Ins | novel | c.1129_1130insATTCA | p.Val377AspfsTer30 | p.V377Dfs*30 | Q8TBB6 | protein_coding | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| SLC7A14 | insertion | In_Frame_Ins | novel | c.1127_1128insTATTTT | p.His376_Val377insIlePhe | p.H376_V377insIF | Q8TBB6 | protein_coding | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC7A14 | SNV | Missense_Mutation | rs115446306 | c.1548N>C | p.Met516Ile | p.M516I | Q8TBB6 | protein_coding | tolerated(0.28) | benign(0.006) | TCGA-C5-A1BJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |